Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations

Fig. 1

JAKi exposure curves for select cytokines. The number of hours per day JAKi concentrations are above IC50 values is shown for IL-21/pSTAT3 in NK cells (a), IL-3/pSTAT5 in monocytes (b), GM-CSF/pSTAT5 in monocytes (c), IL-6/pSTAT3 in CD4+ T cells (d), and IFN-γ/pSTAT1 in monocytes (e). Panels ae include the average daily percent STAT inhibition. Protein binding was accounted for in the calculation of hours per day above IC50 and average daily percent STAT inhibition, and the IC50 values were corrected for the compound-bound proportion. *p < 0.01, **p < 0.001, ***p < 0.0001 compared to baricitinib 2 mg; p < 0.01, ††p < 0.001, †††p < 0.0001 compared to baricitinib 4 mg. Bari, baricitinib; BID, twice daily; GM-CSF, granulocyte-macrophage colony-stimulating factor; h, hours; IC50, half maximum inhibitory concentration; IFN, interferon; IL, interleukin; JAK, Janus kinase; JAKi, JAK inhibitor; NK, natural killer; pSTAT, phosphorylated STAT; QD, once daily; STAT, signal transducer and activator of transcription; Tofa, tofacitinib; Upa, upadacitinib

Back to article page